News & Updates
Filter by Specialty:
Add-on ibrutinib ENRICHes rituximab treatment effect for previously untreated MCL
In the phase II/III ENRICH trial, first-line (1L) ibrutinib with rituximab (IR) demonstrates superiority over rituximab plus chemotherapy (R-chemo; either R-CHOP* or bendamustine**-R) in older patients with previously untreated mantle cell lymphoma (MCL).
Add-on ibrutinib ENRICHes rituximab treatment effect for previously untreated MCL
21 Jan 2025
Increasing breast density elevates cancer risk
Women with large breasts are at greater risk of developing breast cancer, reveals a study, indicating the important role of mammographic density as first measured in determining subsequent risk.
Increasing breast density elevates cancer risk
20 Jan 2025
Risk-reducing surgeries tied to improved outcomes in BRCA carriers with young-onset BC
A large global study provides evidence that risk-reducing mastectomy (RRM) and/or risk-reducing salpingo-oophorectomy (RRSO) is associated with improved survival outcomes in young women diagnosed with breast cancer (BC) at or before 40 years of age who were harbouring germline BRCA1 and/or BRCA2 pathogenic variants (PVs).
Risk-reducing surgeries tied to improved outcomes in BRCA carriers with young-onset BC
20 Jan 2025
CAR T-cell therapy may overcome poor prognosis tied to conventional tiNHL therapies
A real-world study presented at ASH 2024 shows that CD19 chimeric antigen receptor (CAR) T-cell therapy is highly effective and has an acceptable toxicity profile for individuals with transformed indolent non-Hodgkin lymphoma (tiNHL).
CAR T-cell therapy may overcome poor prognosis tied to conventional tiNHL therapies
17 Jan 2025
Add-on palbociclib may overcome resistance to anti-HER2 Tx, ET in HR+, HER2+ mBC
The addition of the CDK4/6 inhibitor palbociclib to anti-HER2 and endocrine therapy (ET) significantly improves progression-free survival (PFS) in patients with hormone receptor-positive, HER-positive (HR+, HER+) metastatic breast cancer (mBC) in the first-line setting, according to the results of the phase III AFT-38 PATINA trial.